Navigation Links
DNAtrix, Inc. to Present Clinical Study Results for DNX-2401 (Delta 24-RGD), A Conditionally Replication-Competent Adenovirus
Date:6/17/2013

HOUSTON, June 17, 2013 /PRNewswire/ -- DNAtrix Inc., experts in oncolytic virus development, today announced that its CEO will present clinical data on the company's lead product, DNX-2401, at the Replicating Oncolytic Virus Therapeutic meeting in Quebec City, Canada on June 18, 2013.

Dr. Frank Tufaro, DNAtrix's CEO and a leader in the field of oncolytic virus therapy, will present results from a clinical study entitled A PHASE I TRIAL OF A CONDITIONALLY REPLICATION-COMPETENT ADENOVIRUS DNX-2401 (FORMERLY KNOWN AS DELTA-24-RGD) FOR RECURRENT MALIGNANT GLIOMAS that evaluated DNX-2401 for patients diagnosed with recurrent glioblastoma. Dr. Tufaro will present study data indicating that DNX-2401 has been well tolerated in 37 patients with no dose-limiting toxicity. Additionally, DNX-2401 has demonstrated highly impressive activity and efficacy.

"We are extremely pleased to have participated in bringing DNX-2401 into the clinic, and are encouraged by the results from this clinical study," said Dr. Tufaro. "DNX-2401 has not only revealed a positive safety profile but also an ability to selectively kill glioblastoma cells. This is exciting because it can lead to complete tumor destruction."

About Glioblastoma and DNX-2401
Glioblastoma is a devastating primary brain tumor resistant to conventional therapies and the second most common cause of death from intracranial disease. The lack of effective therapy for brain tumors has led to intense investigations of novel therapeutic approaches that use vectors and recombinant viruses. Oncolytic virus therapy is based on the concept of using live viruses to selectively infect and replicate in cancer cells, with minimal destruction of normal tissue. Replication amplifies the input dose of the oncolytic virus and helps spread the agent to adjacent tumor cells. DNX-2401, a conditionally replication-competent adenovirus, is being developed for the treatment of several cancer indications including patients with recurrent glioblastoma. DNX-2401 is the culmination of more than a decade of scientific and clinical research and is the most potent and effective oncolytic virus delivered to human brain tumors to date.  DNAtrix will initiate a Phase II clinical study later this year.

About DNAtrix, Inc.
DNAtrix is a company developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company located in Houston, Texas and San Diego, California. For more information, please visit the Company's website at http://www.dnatrix.com.

DNAtrix, Inc. Contact
Frank Tufaro, Ph.D.
Chief Executive Officer
ftufaro@dnatrix.com
(858) 342-6577


'/>"/>
SOURCE DNAtrix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
3. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
4. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
10. Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... ... DC ... th – Monday, September 18 th .The Brain Tumor Foundation (BTF) ... to the public.Where:  BTF,s Mobile MRI Unit – ... NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early Detection ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly and ... actions to streamline operations to more efficiently focus ... its cost structure. Global workforce reductions, including those ... expected to impact approximately 3,500 positions. ... expects annualized savings of approximately $500 million that ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), ... partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry technology ... leading mobile spirometry platform and Novartis, commitment to address the ... ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... to announce the next generation for LASIK in Manhattan with Contoura Vision, the ... technologically advanced laser systems available in the United States to correct nearsightedness and ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Ministry of ... gripping look at the religious stand in the sensitive matter of sexual discrimination, ... “The Ministry of Reconciliation: A Compassionate and Realistic Approach to Evangelizing the LGBTQ ...
(Date:9/25/2017)... , ... September 25, 2017 , ... The trend-spotters, tastemakers, ... REBBL®, maker of organic coconut-milk based super herb drinks, with the new NEXTY Gold ... was the inaugural year for the NEXTY Gold, which is reserved for just those ...
(Date:9/25/2017)... Monica, CA (PRWEB) , ... September 25, 2017 ... ... Me” music video on Thursday, September 28, 2017 to deliver a powerful message ... It On film Franchise. , Feature film writer/director Robert Adetuyi (Beat the World, ...
(Date:9/24/2017)... , ... September 23, 2017 , ... Throughout the United ... harm. , Every day, physicians, nurses and other providers work to give the ... innovative industry processes. , But U.S. Senators today are threatening to tie our ...
Breaking Medicine News(10 mins):